Early functional orthodontic treatment of bad oral habits with AMCOP&reg; bio-activators

A. Patano; F. Cardarelli; V. Montenegro; S. Ceci; A.D. Inchingolo; A. Semjonova; G. Palmieri; C. Di Pede; A. Mancini; M.E. Maggiore; L. Nucci; I.R. Bordea; D. Giovanniello; A. Corriero; M. Farronato; G.M. Tartaglia; G. Malcangi; G. Marinelli; F. Piras; F. Lorusso; A. Scarano; F. Angiero; K. Ferati; A. Bexheti-Ferati; A. Galderisi; B. Rapone; A.M. Inchingolo; D. Di Venere; G. Dipalma; F. Inchingolo

doi:10.23812/j.biol.regul.homeost.agents.202236.2S3.10

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

Early functional orthodontic treatment of bad oral habits with AMCOP® bio-activators

A. Patano, F. Cardarelli, V. Montenegro, S. Ceci, A.D. Inchingolo, A. Semjonova, G. Palmieri, C. Di Pede, A. Mancini, M.E. Maggiore, L. Nucci, I.R. Bordea, D. Giovanniello, A. Corriero, M. Farronato, G.M. Tartaglia, G. Malcangi, G. Marinelli, F. Piras, F. Lorusso, A. Scarano, F. Angiero, K. Ferati, A. Bexheti-Ferati, A. Galderisi, B. Rapone, A.M. Inchingolo, D. Di Venere, G. Dipalma, F. Inchingolo

Article ID: 6307
Vol 36, Issue 2S3, 2022

DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.202236.2S3.10

Received: 9 May 2022; Accepted: 9 May 2022; Available online: 9 May 2022; Issue release: 9 May 2022

Abstract

Genetic and environmental factors influence craniofacial growth. The presence of bad habits such as fingeror pacifier sucking, atypical swallowing, oral breathing, nail-biting and abnormal postures play an essential rolein developing malocclusions. The severity and type of malocclusion are related to the age of the patient and thefrequency, duration and intensity of the spoiled habit. The most common malocclusions are: posterior crossbite,transverse contraction of the palate, anterior open bite, and augmented overjet. Eliminating oral habits withan interceptive functional treatment allows for restoring the correct development of the bone bases and normalocclusion. Elastodontic devices represent a valid tool to correct neuromuscular dysfunctions and re-educaterespiratory, swallowing, speech and masticatory functions, performing a functional, orthopaedic action.

Keywords

interceptive orthodontics;elastodontics;elastodontic therapy;elastodontic appliances;bad oral habits;atypical swallowing;oral breathing;finger sucking

References

Supporting Agencies

Copyright (c) 2022 A. Patano, F. Cardarelli, V. Montenegro, S. Ceci, A.D. Inchingolo, A. Semjonova, G. Palmieri, C. Di Pede, A. Mancini, M.E. Maggiore, L. Nucci, I.R. Bordea, D. Giovanniello, A. Corriero, M. Farronato, G.M. Tartaglia, G. Malcangi, G. Marinelli, F. Piras, F. Lorusso, A. Scarano, F. Angiero, K. Ferati, A. Bexheti-Ferati, A. Galderisi, B. Rapone, A.M. Inchingolo, D. Di Venere, G. Dipalma, F. Inchingolo

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...